Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Graft Polymer (UK) PLC ( (GB:GPL) ) just unveiled an update.
Graft Polymer (UK) Plc announced the successful approval of a name change to Solvonis Therapeutics plc following a general meeting. This change signifies a strategic rebranding effort as the company continues to focus on its mission to improve outcomes for individuals with mental health disorders. The shareholders remain unaffected by the name change, with share certificates still valid, emphasizing stability and continuity for stakeholders.
More about Graft Polymer (UK) PLC
Graft Polymer (UK) Plc is an innovative biotechnology company focused on developing intellectual property for the treatment of mental health and substance use disorders. The company co-develops therapeutics specifically targeting mental health disorders, with an initial emphasis on trauma-related conditions like PTSD, affecting millions in the US, UK, and EU markets.
YTD Price Performance: -7.32%
Average Trading Volume: 26,477,466
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £4.36M
See more data about GPL stock on TipRanks’ Stock Analysis page.